Brandon Capital and the MRCF

Brandon Capital Partners is a venture capital firm managing the Medical Research Collaboration Fund (MRCF) which provides seed and venture capital investment to support the development and growth of Australian life science companies. Established in late 2007, the MRCF is a unique collaboration between major Australian superannuation funds, over 50 leading medical research institutes and research hospitals in Australia and New Zealand. The MRCF supports the development and commercialisation of early-stage biomedical discoveries originating from these member research organisations, providing both capital and expertise to guide the successful development of new therapies. MRCF3 was established with support from the Australian and New Zealand governments, as well as the state governments of Victoria, New South Wales, Western Australia, Queensland, South Australia and the Australian Capital Territory. The current MRCF funds being invested are the MRCF3 ($200 million) for early stage opportunities and the MRCF-BTF ($230 million) for maturing technologies that have progressed to clinical development.
Visit

Uniseed

Uniseed is a venture fund operating at the Universities of Melbourne, Queensland, New South Wales and Sydney, as well as the CSIRO. Uniseed’s mandate is to facilitate the commercialisation of research partner generated intellectual property by targeted investment in highly promising technologies. Uniseed’s investments cover a range of technology sectors. To date, the fund has exited four investments through trade sales, including a product for nerve pain (Spinifex Pharmaceuticals acquisition by Novartis for US$200m up-front plus milestone payments); a drug in development to treat fibrosis (Fibrotech Therapeutics sale to Shire plc for US$75m up-front plus milestone payments); an IT security technology (Vintela sale to Quest Software Inc. for US$75m); new semi-conductor technology (Fultec sale to Bourns Semiconductor Inc.) and an investment (Hatchtech) through an asset sale to Dr. Reddy’s Laboratories in a deal worth $200m. A number of companies in Uniseed’s investment portfolio have products on the market, including Hydrexia, BT Imaging and Smart Sparrow, while other companies are collaborating with global corporate leaders in their respective fields (Nexgen Plants, Q-Sera, TenasiTech). For more information, visit www.uniseed.com.
Visit